Comparative efficacy of vericiguat to sacubitril/valsartan for patients with heart failure reduced ejection fraction: Systematic review and network meta-analysis

沙库比林、缬沙坦 沙库比林 缬沙坦 医学 射血分数 心力衰竭 内科学 荟萃分析 心脏病学 血压
作者
Dong-Won Kang,Seung‐Ho Kang,Kyungmin Lee,Kyung-ae Nam,Eui-Soon Kim,Jong‐Chan Youn,Sun‐Kyeong Park
出处
期刊:International Journal of Cardiology [Elsevier BV]
卷期号:400: 131786-131786 被引量:7
标识
DOI:10.1016/j.ijcard.2024.131786
摘要

Abstract

Background

Despite the established efficacy of vericiguat compared to placebo, uncertainties remain regarding its comparative efficacy to sacubitril/valsartan for patients with heart failure reduced ejection fraction (HFrEF). This study aimed to assess the relative efficacy of vericiguat and sacubitril/valsartan through a systematic review, network meta-analysis, and non-inferiority tests.

Methods

A systematic review was conducted to identify the randomized phase 3 clinical trials involving vericiguat and sacubitril/valsartan. The hazard ratios (HRs) with 95% confidence intervals (CI) for cardiovascular death (CVD) and hospitalization due to HF (hHF) were extracted from these trials and synthesized via network meta-analysis. Non-inferiority testing of vericiguat was performed using a fixed-margin method with a predefined non-inferiority margin (1.24). Sensitivity analyses explored the impact of the time from hHF to screening.

Results

Among the 1366 studies, two trials (VICTORIA and PARADIGM-HF) met the inclusion criteria. Network meta-analysis demonstrated that the HR for CVD or hHF with vericiguat did not significantly differ from that for sacubitril/valsartan (HR: 0.88, 95% CI:0.62–1.23). The upper limit of the 95% CI was less than the predefined margin of 1.24, confirming vericiguat's non-inferiority to sacubitril/valsartan. Sensitivity analyses affirmed the robustness of the base-case results.

Conclusion

Vericiguat exhibited a comparable risk of CVD or hHF when contrasted with sacubitril/valsartan. Importantly, in patients with HFrEF, vericiguat's efficacy was not statistically inferior to that of sacubitril/valsartan. These findings reinforce the potential of vericiguat as a viable treatment option for this patient population.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
嘟噜发布了新的文献求助10
1秒前
1秒前
不想上班发布了新的文献求助10
1秒前
王饱饱发布了新的文献求助10
2秒前
2秒前
jie发布了新的文献求助10
2秒前
上官若男的应助被机灵天宇采纳,获得10
2秒前
淳于易形完成签到,获得积分10
2秒前
kento发布了新的文献求助10
2秒前
Echo发布了新的文献求助10
2秒前
molihuakai的应助被酷酷柚子采纳,获得10
2秒前
大个的应助被单纯的晓刚采纳,获得10
3秒前
Hello的应助被wyc采纳,获得10
3秒前
snow完成签到,获得积分10
3秒前
武子琪完成签到,获得积分10
3秒前
4秒前
MHB完成签到,获得积分10
4秒前
4秒前
4秒前
星语完成签到,获得积分10
5秒前
chchjust发布了新的文献求助10
5秒前
科研通AI6.3的应助被xr采纳,获得10
5秒前
5秒前
wanci的应助被msk采纳,获得10
5秒前
HapenLIAO完成签到,获得积分10
5秒前
7秒前
7秒前
7秒前
8秒前
大个的应助被勤恳觅松采纳,获得10
8秒前
9秒前
CarryLJR发布了新的文献求助10
9秒前
9秒前
bkagyin的应助被赤壁采纳,获得10
9秒前
realwader完成签到,获得积分10
9秒前
脑洞疼的应助被灰暗格调采纳,获得10
10秒前
乐观的颦发布了新的文献求助10
10秒前
10秒前
丘比特的应助被chi采纳,获得10
11秒前
搜集达人的应助被周博士采纳,获得10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178203
求助须知:如何正确求助?哪些是违规求助? 9568998
关于积分的说明 21802098
捐赠科研通 7773088
什么是DOI,文献DOI怎么找? 3432711
关于科研通互助平台的介绍 2556748
邀请新用户注册赠送积分活动 2478259